Latest National Institute for Health and Clinical Excellence Stories
COVENTRY health chiefs are supporting a draft decision to reject four new cancer drugs for patients with advanced kidney cancer. The National Institute for Health and Clinical Excellence (Nice) decided that sunitinib, bevacizumab, sorafenib and Torisel are not a cost-effective use of NHS cash.
By Barry Nelson A CANCER patient who has survived in the past year because of a wonder drug has condemned plans to deny it to other patients because of the cost. Stan Craddock, 63, from Darlington, said he survived the past ten months because of the drug Sutent.
Britain's National Health Service said it rejected four new drugs designed to treat advanced kidney cancer because the cost is too high.
By Ian Johnston CAMPAIGNERS EXPRESSED outrage yesterday at a decision to deny four drug treatments to NHS patients with advanced kidney cancer.
By JEREMY LAURANCE The big question Why are we asking this now? CANCER CHARITIES, kidney specialists and campaigners were outraged yesterday when the National Institute for Clinical Excellence (Nice), announced that it had rejected four new drugs for advanced kidney cancer as too expensive for the NHS.
PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs. Charities expressed outrage at the decision. (c) 2008 Liverpool Echo.
By JANE KIRBY PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published yesterday.
By Greg Tindle A WELSH cancer expert has described as "an outrage" plans to deny patients with advanced kidney cancer four types of drug treatment on the NHS.
By Emma Brady Midland cancer experts have hit out at a decision to deny kidney cancer patients four drugs under new NHS guidelines issued yesterday.
By HELEN RAE PATIENTS with advanced kidney cancer will be denied four life- extending treatments on the NHS because they are not cost effective.
- The parings of haberdine; also, any kind of fragments.